This is a working overview of ACTH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
=== Veterinary use === Veterinary clinics use cold laser devices to treat a wide variety of ailments, from arthritis to wounds, on dogs and cats. In spite of this, little research has been done on its effects. According to Brennen McKenzie, president of the Evidence-Based Veterinary Medicine Association, as of 2016 "research into cold laser in dogs and cats is sparse and generally low quality. Most studies are small and have minimal or uncertain controls for bias and error". He allowed that some studies show promising results, while concluding that current evidence is not sufficient to support routine clinical use.
== Sources == This article incorporates text from a free content work. Licensed under CC BY-SA IGO 3.0 (license statement/permission). Text taken from World Food and Agriculture – Statistical Yearbook 2023, FAO, FAO.
26 May – Following a trial at Derby Crown Court, Stephen Boden and Shannon Marsden, who killed their ten-month-old son, Finley Boden, on Christmas Day 2020, 39 days after he was returned to them by social services, are sentenced to life imprisonment with minimum terms of 29 years and 27 years respectively. Following a trial at the Old Bailey, Jake Drummond is sentenced to life imprisonment with a minimum of 32 years for the murder of 15-month-old Jacob Lennon. Drummond's partner, and Jacob's mother, Louise Lennon, is sentenced to 10 years for causing or allowing her son's death. Presenter Phillip Schofield admits to the Daily Mail that he had an affair with a "much younger man" who worked as a runner on This Morning, subsequently apologising and resigning from ITV. 27 May – The 2023 Premiership Rugby final is disrupted when protestors from Just Stop Oil run onto the pitch at Twickenham Stadium and throw orange powder paint. Two men are subsequently charged in connection with the incident. 29 May – The Metropolitan Police Service confirms it will stop attending emergency calls relating to mental health from September in order to free up officers' time. 31 May – 2023 Bournemouth beach incident, Two people die and eight others are injured during an incident at a beach in Bournemouth.
This is a timeline of women in science, spanning from ancient history up to the 21st century. While the timeline primarily focuses on women involved with natural sciences such as astronomy, biology, chemistry, and physics, it also includes women from the social sciences (e.g. sociology, psychology), and the formal sciences (e.g. mathematics, computer science), as well as notable science educators and medical scientists. The chronological events listed in the timeline relate to both scientific achievements and gender equality within the sciences.
Sources: en.wikipedia.org
Lithium is a teratogen, which can cause birth defects in a small number of newborns. Case reports and several retrospective studies have demonstrated possible increases in the rate of a congenital heart defects (CHDs) including Ebstein's anomaly if taken during the first trimester of pregnancy. The risk is dose-dependent: in the 2017 AMX registry study, the relative risk of "any malformations" is 1.11 in those taking no more than 600 mg of lithium carbonate daily, 1.60 in those taking 601–900 mg daily, and 3.22 in those taking more than 900 mg daily. The first two numbers do not indicate a statistically significant association. In a 2018 meta-analysis, there was a statistically significant 62% increase (95% CI: 12%–133%) in congenital malformations in general, but not for cardiac malformations specifically. Exposure during any part of the pregnancy is associated with a slight but statistically significant increase in the risks of preterm birth and of a larger-than-usual baby at birth. Lithium is effective for preventing relapse during and after pregnancy. As the risks of stopping Lithium can be significant, patients are sometimes recommended to stay on this medicine while pregnant. Careful weighing of the risks and benefits should be made in consultation with a psychiatric physician. The relatively low teratogenic risk of lithium allows such a choice. The decision should be made before the start of pregnancy, as there is no reason for stopping lithium once the pregnancy has started.
=== Early life === Frederik Dag Arfst Paulsen was born on 30 October 1950 in Stockholm, Sweden, as a Swedish citizen. His father was Frederik Paulsen Sr, the founder of Ferring Pharmaceuticals. Paulsen grew up in Sweden, with his father and his father's second wife, Dr. Eva Wolf Frandsen – one of the founding researchers at Ferring. He attended school in Sweden and then went on to study chemistry at the Christian Albrecht University in Kiel, (Germany) and business administration at Lund University in Sweden. He received his doctoral degree in Demography from Ecole des Hautes Etudes en Sciences Sociales in Paris, France.
In January and February 1973, King Crimson recorded Larks' Tongues in Aspic in London; the album was released that March. The band's new sound was exemplified by the album's two-part title track, which emphasised the sharp instrumental interplay of the band and drew influence from modernist classical music, noisy free improvisation, and heavy metal. The record displayed Muir's unusual approach to percussion, which included a self-modified drum kit, assorted toys, a bullroarer, mbira, gongs, balloons, a thunder sheet and chains. On stage, Muir also employed unpredictable, manic movements, bizarre clothing, and fake blood capsules which he occasionally spit or applied to the head; this was the sole example of such on-stage theatrics in the band's long history. The album reached No. 20 in the UK and No. 61 in the US. After a period of further touring, Muir departed in 1973, quitting the music industry altogether. Muir told King Crimson's management that a musician's life was not for him, and he had chosen to join a Scottish Buddhist monastery. He offered to serve a period of notice which the management declined. Instead of giving the real reason for Muir's departure, the management informed the rest of the band and the public that Muir had sustained an onstage injury caused by a gong landing on his foot.
March 24: Law concerning the vagrancy of minors under eighteen years of age. (in the Official Journal of March 28–29–30, 1921). July 24: Law preventing and settling conflicts between French law and local Alsace-Lorraine law in private matters: the applicable law for a married woman is that which applies to her husband (regarding status and legal capacity). December 20, 1922: Law amending Articles 334 and 335 of the Penal Code to include punishment for attempted offenses related to the so-called "trafficking of women." 1923
=== 3. Cementum === Cementum is a thin, calcified, avascular connective tissue that covers the root surface of the tooth. Its primary function is to serve as an attachment medium for periodontal ligament collagen fibers, thereby securing the tooth within the alveolar socket. Under normal conditions, cementum is located subgingivally and is not exposed to the oral environment. However, gingival recession associated with periodontal disease may expose cementum, increasing the risk of dentinal hypersensitivity and root caries.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.